2013 Update of the 2011 American college of rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications

Arthritis Care and Research

Volumn 65, Issue 10, 2013, Pages 1551-1563

  Ringold, Sarah ^a   Weiss, Pamela F ^b   Beukelman, Timothy ^c   Dewitt, Esi Morgan ^d   Ilowite, Norman T ^e   Kimura, Yukiko ^f   Laxer, Ronald M ^g   Lovell, Daniel J ^d   Nigrovic, Peter A ^h   Robinson, Angela Byun ⁱ   Vehe, Richard K ^j  

^a SEATTLE CHILDREN S HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY   (United States)

^j UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; BIOLOGICAL PRODUCT; CALCINEURIN INHIBITOR; CANAKINUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AMERICAN COLLEGE OF RHEUMATOLOGY; ARTICLE; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MEDICAL TECHNOLOGY; MONOTHERAPY; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PROFESSIONAL KNOWLEDGE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOLOGY; SCREENING TEST; TREATMENT OUTCOME; TUBERCULOSIS;

ARTHRITIS, JUVENILE; BIOLOGICAL PRODUCTS; CHILD; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MASS SCREENING; PREDICTIVE VALUE OF TESTS; RHEUMATOLOGY; RISK FACTORS; SOCIETIES, MEDICAL; TUBERCULOSIS; UNITED STATES;

EID: 84885014310     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22087     Document Type: Article

References (77)

1. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63: 465-82.
2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
3. Singh-Grewal D, Schneider R, Bayer N, Feldman BM,. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 2006; 54: 1595-601.
4. Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F,. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000; 27: 491-6.
5. Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED, Laxer RM, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000; 43: 2402-9.
6. Mellins ED, Macaubas C, Grom AA,. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011; 7: 416-26.
7. Martini A,. Systemic juvenile idiopathic arthritis. Autoimmun Rev 2012; 12: 56-9.
8. Behrens EM, Beukelman T, Paessler M, Cron RQ,. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34: 1133-8.
9. Behrens EM, Beukelman T, Gallo L, Spangler J, Rosenkranz M, Arkachaisri T, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 2008; 35: 343-8.
10. Bennett TD, Fluchel M, Hersh AO, Hayward KN, Hersh AL, Brogan TV, et al. Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis. Arthritis Rheum 2012; 64: 4135-42.
11. Sawhney S, Woo P, Murray KJ,. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001; 85: 421-6.
12. Fitch K, Bernstein S, Aguilar M, Burnand B, LaCalle J,. The RAND/UCLA appropriateness method user's manual. Santa Monica (CA): RAND; 2001.
13. Sampson M, McGowan J, Lefebvre C, Moher DG,. PRESS: peer review of electronic search strategies. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2008.
14. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396-406.
15. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2385-95.
16. CEBM, Centre for Evidence-Based Medicine. Oxford Centre for Evidence-Based Medicine: levels of evidence (March 2009). Oxford (UK): Oxford Centre for Evidence-Based Medicine; 2009. URL: http://www.cebm.net/index.aspx?o= 1025.
17. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 747-54.
18. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63: 545-55.
19. Hedrich CM, Bruck N, Fiebig B, Gahr M,. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Rheumatol Int 2012; 32: 3525-30.
20. Pay S, Turkcapar N, Kalyoncu M, Simsek I, Beyan E, Ertenli I, et al. A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol 2006; 25: 639-44.
21. Picco P, Gattorno M, Buoncompagni A, Pistoia V, Borrone C,. 6-methylprednisolone 'mini-pulses': a new modality of glucocorticoid treatment in systemic onset juvenile chronic arthritis. Scand J Rheumatol 1996; 25: 24-7.
22. Swart JF, Barug D, Mohlmann M, Wulffraat NM,. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Ther 2010; 10: 1743-52.
23. Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009; 15: 161-4.
24. Ohlsson V, Baildam E, Foster H, Jandial S, Pain C, Strike H, et al. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA) [letter]. Rheumatology (Oxford) 2008; 47: 555-6.
25. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J,. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86.
26. Merlin E, Berthomieu L, Dauphin C, Stephan JL,. Cardiac tamponade in a child with systemic-onset juvenile idiopathic arthritis: dramatic improvement after interleukin-1 blockade by anakinra [letter]. Pediatr Cardiol 2011; 32: 862-3.
27. Mirkinson LJ, Nagle D, Kadom N, Jones OY,. Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis. J Clin Rheumatol 2006; 12: 83-6.
28. Verbsky JW, White AJ,. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004; 31: 2071-5.
29. Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58: 1505-15.
30. Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67: 302-8.
31. Ruperto N, Ravelli A, Castell E, Gerloni V, Haefner R, Malattia C, et al. Cyclosporine A in juvenile idiopathic arthritis: results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol 2006; 24: 599-605.
32. Ravelli A, Moretti C, Temporini F, Rossi F, Magni-Manzoni S, Pistorio A, et al. Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis. Clin Exp Rheumatol 2002; 20: 569-72.
33. Gerloni V, Cimaz R, Gattinara M, Arnoldi C, Pontikaki I, Fantini F,. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis: results of a 10-year prospective study. Rheumatology (Oxford) 2001; 40: 907-13.
34. Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997; 24: 2436-43.
35. Pistoia V, Buoncompagni A, Scribanis R, Fasce L, Alpigiani G, Cordone G, et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis: results of a preliminary study. Clin Exp Rheumatol 1993; 11: 203-8.
36. Ostensen M, Hoyeraal HM, Kass E,. Tolerance of cyclosporine A in children with refractory juvenile rheumatoid arthritis. J Rheumatol 1988; 15: 1536-8.
37. Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al, for the Paediatric Rheumatology International Clinical Trials Organisation. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012; 64: 557-67.
38. Bloom BJ, Alario AJ, Miller LC,. Intra-articular corticosteroid therapy for juvenile idiopathic arthritis: report of an experiential cohort and literature review. Rheumatol Int 2011; 31: 749-56.
39. Lanni S, Bertamino M, Consolaro A, Pistorio A, Magni-Manzoni S, Galasso R, et al. Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. Rheumatology (Oxford) 2011; 50: 1627-34.
40. Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000; 43: 1849-57.
41. Russo RA, Katsicas MM,. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009; 36: 1078-82.
42. Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005; 32: 935-42.
43. Inaba Y, Ozawa R, Aoki C, Imagawa T, Mori M, Hara R, et al. Radiologic analysis of the effect of tocilizumab on hands and large joints in children with systemic juvenile idiopathic arthritis. Mod Rheumatol 2012. E-pub ahead of print.
44. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 818-25.
45. Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005; 7: R1281-8.
46. Inaba Y, Ozawa R, Imagawa T, Mori M, Hara Y, Miyamae T, et al. Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment. Ann Rheum Dis 2011; 70: 1693-5.
47. De La Torre M, Arboleya L, Pozo S, Pinto J, Velasco J,. Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephrotic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis. NDT Plus 2011; 4: 178-80.
48. Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, et al. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan [letter]. Ann Rheum Dis 2013; 72: 627-8.
49. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006.
50. Becker ML, Rose CD, Cron RQ, Sherry DD, Bilker WB, Lautenbach E,. Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens. J Rheumatol 2010; 37: 870-5.
51. Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G,. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken) 2012; 64: 1349-56.
52. Foeldvari I, Wierk A,. Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. J Rheumatol 2010; 37: 1763-7.
53. Jahan A, Dewan V, Yadav TP,. Leflunomide in systemic onset juvenile idiopathic arthritis. Indian Pediatr 2012; 49: 750-2.
54. Record JL, Beukelman T, Cron RQ,. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series [letter]. J Rheumatol 2011; 38: 180-1.
55. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al, for the Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010; 62: 1792-802.
56. Ruperto N, Lovell DJ, Li T, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, et al, for the Paediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCGS). Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2010; 62: 1542-51.
57. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383-91.
58. Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009; 28: 129-37.
59. Papsdorf V, Horneff G,. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford) 2011; 50: 214-21.
60. Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011; 306: 2340-7.
61. Zuber Z, Rutkowska-Sak L, Postepski J, Dobrzyniecka B, Opoka-Winiarska V, Kobusinska K, et al. Etanercept treatment in juvenile idiopathic arthritis: the Polish registry. Med Sci Monit 2011; 17: SR35-42.
62. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ,. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2011; 50: 417-9.
63. Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F,. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 2011; 17: 23-7.
64. Kelly A, Ramanan AV,. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008; 4: 615-20.
65. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM,. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 1996; 129: 750-4.
66. Mizrahi M, Ben-Chetrit E,. Relapsing macrophage activating syndrome in a 15-year-old girl with Still's disease: a case report. J Med Case Rep 2009; 3: 138.
67. Hur M, Kim YC, Lee KM, Kim KN,. Macrophage activation syndrome in a child with systemic juvenile rheumatoid arthritis. J Korean Med Sci 2005; 20: 695-8.
68. Ravelli A, De Benedetti F, Viola S, Martini A,. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 1996; 128: 275-8.
69. Cortis E, Insalaco A,. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl 2006; 95: 38-41.
70. Cuende E, Vesga JC, Perez LB, Ardanaz MT, Guinea J,. Macrophage activation syndrome as the initial manifestation of systemic onset juvenile idiopathic arthritis [letter]. Clin Exp Rheumatol 2001; 19: 764-5.
71. Hadchouel M, Prieur AM, Griscelli C,. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 1985; 106: 561-6.
72. Ilowite NT, Sandborg CI, Feldman BM, Grom A, Schanberg LE, Giannini EH, et al. Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology. Pediatr Rheumatol Online J 2012; 10: 31.
73. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005; 146: 598-604.
74. Davi S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011; 38: 764-8.
75. Red Book: 2009 report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village (IL): American Academy of Pediatrics; 2009.
76. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K,. Updated guidelines for using interferon γ release assays to detect Mycobacterium tuberculosis infection: United States, 2010. MMWR Recomm Rep 2010; 59: 1-25.
77. DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al, on behalf of the Juvenile Idiopathic Arthritis Disease-Specific Research Committee of the Childhood Arthritis and Rheumatology Research Alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1001-10.